TELA Bio, a medical technology company specializing in soft-tissue reconstruction, announced it will release its third quarter 2026 financial results on November 10, 2026. The company will host a conference call and webcast at 4:30 p.m. ET to discuss the results and provide a corporate update. Investors can register online to participate and access the live webcast or replay via TELA Bio's investor website. This update is important for stakeholders tracking the company’s financial health and strategic progress.
TELA Bio's upcoming third quarter 2026 financial results are announced alongside Pluang's health sector snapshot. For readers following health stocks, here is Pluang's market snapshot as of Oct 28, 2026 03:11 WIB: out of 150 priced US health-sector stocks, 88 rose and 62 fell. Notable movers include IBRX at USD 8.61 with a 10.24% increase and 100% buy order activity, TWST at USD 159.95 up 10.12% with 100% buy orders, and MRVI at USD 8.21 rising 8.38%.
The global drone defense system market is projected to grow from $4.72 billion in 2025 to $18.19 billion by 2030, driven by increasing unauthorized drone incidents and demand for advanced detection and countermeasure technologies. Growth is fueled by...
Eli Lilly has outpaced Novo Nordisk in the GLP-1, obesity, and Type 2 Diabetes market, achieving a $1.21 trillion valuation. While Novo Nordisk's share price has fallen back after earlier gains and revenue growth remains flat, its management's strate...
argenx SE announced it will stop its Phase 3 UNITY study of efgartigimod subcutaneous for moderate-to-severe Sjögren's disease after an independent committee found the trial unlikely to meet its primary goal. This decision caused the company's stock ...
Pomerantz LLP is investigating DaVita Inc. for potential securities fraud following a sharp stock price drop triggered by a new U.S. federal strategy targeting the dialysis market. The Department of Health and Human Services announced a plan to incre...
Pomerantz LLP is investigating ClearPoint Neuro and its executives for possible securities fraud following a significant stock price drop. The decline occurred after ClearPoint's partner, uniQure, announced that their Huntington's disease treatment f...
